Literature DB >> 8615079

Dystrophin-positive muscle fibers following C2 myoblast transplantation into mdx nude mice.

Y Hagiwara1, Y Mizuno, M Takemitsu, T Matsuzaki, I Nonaka, E Ozawa.   

Abstract

To determine when and how the dystrophin-positive muscle fibers are formed after myoblast transplantation into dystrophin-negative muscles, the tibialis anterior (TA) muscle from mdx nude mouse was chronologically examined after C2 myoblast transplantation by immunohistochemical and glucose 6-phosphate isomerase (GPI) isoenzyme analyses. The host TA muscle transplanted with C2 myoblasts became necrotic with accumulation of basic fibroblast growth factor in the necrotic areas. This may stimulate concomitant proliferation of the host satellite cells and C2 myoblasts. Small dystrophin-positive muscle fibers appeared in the necrotic areas 3 days after transplantation. This TA muscle contained two different kinds of homodimer GPI isoenzymes but did not contain the heterodimer, suggesting rare fusion of host and donor cells. The dystrophin-positive muscle fibers in the necrotic areas rapidly increased in number and in size by 7 days, but they were smaller than the original host muscle fibers. They had central nuclei, indicating that they were regenerating fibers. The presence of heterodimer GPI isoenzyme in these muscles indicated that the regenerating fibers were mosaic host/donor muscle fibers. The dystrophin-positive muscle fibers are probably formed first by fusion of donor cells with each other and then later by the fusion of host satellite and donor cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8615079     DOI: 10.1007/bf00318571

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  48 in total

1.  Glycoprotein complex anchoring dystrophin to sarcolemma.

Authors:  M Yoshida; E Ozawa
Journal:  J Biochem       Date:  1990-11       Impact factor: 3.387

Review 2.  Invited review: myoblast transfer: a possible therapy for inherited myopathies?

Authors:  T A Partridge
Journal:  Muscle Nerve       Date:  1991-03       Impact factor: 3.217

Review 3.  Dystrophin abnormalities in Duchenne/Becker muscular dystrophy.

Authors:  E P Hoffman; L M Kunkel
Journal:  Neuron       Date:  1989-01       Impact factor: 17.173

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface.

Authors:  E Bonilla; C E Samitt; A F Miranda; A P Hays; G Salviati; S DiMauro; L M Kunkel; E P Hoffman; L P Rowland
Journal:  Cell       Date:  1988-08-12       Impact factor: 41.582

6.  Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons.

Authors:  H G Lidov; T J Byers; S C Watkins; L M Kunkel
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

7.  New muscle transplant method produces normal twitch tension in dystrophic muscle.

Authors:  P K Law; J L Yap
Journal:  Muscle Nerve       Date:  1979 Sep-Oct       Impact factor: 3.217

8.  The effects of fibroblast growth factors in long-term primary culture of dystrophic (mdx) mouse muscle myoblasts.

Authors:  J Smith; P N Schofield
Journal:  Exp Cell Res       Date:  1994-01       Impact factor: 3.905

9.  Muscle development in mdx mutant mice.

Authors:  J Dangain; G Vrbova
Journal:  Muscle Nerve       Date:  1984 Nov-Dec       Impact factor: 3.217

10.  X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD.

Authors:  S Wakeford; D J Watt; T A Partridge
Journal:  Muscle Nerve       Date:  1991-01       Impact factor: 3.217

View more
  2 in total

1.  A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy.

Authors:  Kumaran Chandrasekharan; Jung Hae Yoon; Ying Xu; Sarah deVries; Marybeth Camboni; Paulus M L Janssen; Ajit Varki; Paul T Martin
Journal:  Sci Transl Med       Date:  2010-07-28       Impact factor: 17.956

2.  Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.

Authors:  Agnieszka Łoboda; Józef Dulak
Journal:  Pharmacol Rep       Date:  2020-07-20       Impact factor: 3.024

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.